Article
Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2013
Veal Gareth J, Errington Julie, Rowbotham Sophie E, Illingworth Nicola A, Malik Ghada, Cole Michael, Daly Ann K, Pearson Andrew D J, Boddy Alan V
Abstract excerpt
PURPOSE: To investigate the feasibility of adaptive dosing and the impact of pharmacogenetic variation on 13-cis-retinoic acid (13-cisRA) disposition in high-risk patients with neuroblastoma. EXPERIMENTAL DESIGN: 13-cisRA (160 mg/m(2) or 5.33 mg/kg/d) was administered to 103 patients ages 21 year...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.